Data from the Phase 1 trial of Neuralstem's (NYSEMKT:CUR) NSI-566 in Amyotrophic Lateral Sclerosis (or "ALS") patients was presented at the 2013 American Neurology Association Meeting in October 2013 and is being published in the Annals of Neurology. While data has been previously reported on the initial trial cohort of 12 ALS subjects who received only lumbar injections, the presentation and manuscript for peer-review describe follow up data for the initial 12 subjects as well as the outcome of the final trial cohorts, which consisted of six patients receiving five cervical injections with half of those patients having previously received 10 lumbar injections.
This is important, because the earlier cohorts in the study were safety assessments. The...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|